SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-23-102245
Filing Date
2023-04-14
Accepted
2023-04-14 17:04:56
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFA14A d448803ddefa14a.htm DEFA14A 27959
2 GRAPHIC g448803g00n06.jpg GRAPHIC 187826
3 GRAPHIC g448803g00n07.jpg GRAPHIC 157807
4 GRAPHIC g448803g0415005406066.jpg GRAPHIC 4236
5 GRAPHIC g448803g0415005406342.jpg GRAPHIC 3493
  Complete submission text file 0001193125-23-102245.txt   516237
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36352 | Film No.: 23821939
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences